science wire

« BACK

Pharmacology



Results 1001 - 1050 of 1530.


Health - Pharmacology - 02.06.2015
Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions
New one-year data for secukinumab, the first IL-17A inhibitor to show significant improvement in ankylosing spondylitis (AS) signs and symptoms, to be presented at European League Against Rheumatism meeting (EULAR) Cosentyx (TM) (secukinumab) data to be revealed in patients with difficult-to-treat psoriasis of the palms, soles and nails at World Congress of Dermatology (WCD) Late-breaking results at WCD include the impact of Xolair (omalizumab)

Pharmacology - Health - 01.06.2015
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy † Recent milestones for Novartis CAR therapy program include initiation of global Phase II multi-center CTL019 study and activation of cell processing facility † Data also highlight preliminary safety and efficacy data for CTL019 in other indications †††††††††††† † Basel, Switzerland,

Health - Pharmacology - 01.06.2015
Novartis presents new data at ASCO for Zykadia and combination of Tafinlar and Mekinist in certain NSCLC patients with unmet needs
In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases , † Tafinlar (dabrafenib) and Mekinist (trame

Health - Pharmacology - 31.05.2015
Combination of Novartis drugs Tafinlar and Mekinist shows significant survival benefit in patients with metastatic melanoma
Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma † Tafinlar and Mekinist in combination achieved

Health - Pharmacology - 21.05.2015
Novartis drug Afinitor extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint † Full results will be submitted for presentation at a major med

Pharmacology - Health - 20.05.2015
Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results - † GEM 1 & 2 studies showed NVA237 pro

Health - Pharmacology - 08.05.2015
Novartis lung cancer drug Zykadia gains EU approval, providing new therapy for certain patients with ALK+ NSCLC
Zykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib † Marketing authorization was based on two studi

Health - Pharmacology - 27.04.2015
Novartis announces Phase III study of Arzerra met primary endpoint of improved progression-free survival in patients with relapsed CLL
Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working † CLL is the most commonly diag

Pharmacology - Business / Economics - 23.04.2015
Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio
Continuing operations saw sales, core operating income and core EPS grow (cc ) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc) Operating income was USD 2.8 billion (-1%, +15% cc) Cor

Health - Pharmacology - 21.04.2015
Data at AAN showed Gilenya high efficacy in achieving ’no evidence of disease activity’ in previously-treated highly-active MS patients
Data at AAN showed Gilenya high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity† (NEDA4)' vs placebo NEDA4 is based on four key measures of relapsing MS (RMS): relapses, MRI lesions, MS-related brain shrinkage and disability progression Separate

Pharmacology - Health - 16.04.2015
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone 20mg
Glatopa is the first FDA-approved, substitutable generic version of Copaxone † 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full range of di

Health - Pharmacology - 16.04.2015
Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States
US Food and Drug Administration (FDA) grants approval of the AcrySof IQ ReSTOR +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the correction of ne

Health - Pharmacology - 15.04.2015
Data in The Lancet show Novartis drug Arzerra plus chlorambucil improved median progression-free survival by 71% in CLL patients
Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in Western countries, accounting for approximately 1 in 4 cases of all leukemia , 75% of CLL patients are over 65 years of age at time of diagnosis and majority have at least one comorbidity such as hyperte

Health - Pharmacology - 13.04.2015
Gilenya data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians
New analysis will confirm high efficacy of Gilenya in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in relapsing MS (RMS) Early data on a novel method to assess motor function in patients with MS and its potential clinical application will also be presented at

Pharmacology - Health - 30.03.2015
Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload
Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment administration fo

Health - Pharmacology - 30.03.2015
Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances the divers

Life Sciences - Pharmacology - 26.03.2015
How genes are permanently silenced by small RNAs
How genes are permanently silenced by small RNAs
Marc BŁhler and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) have elucidated the mechanism underlying small RNA-mediated gene silencing, thus solving a mystery which has been puzzling the research community for over a decade. Back in 2002, the discovery by several research groups that small RNA molecules can shut down clearly defined genome regions was hailed by Science as the Breakthrough of the Year.

Pharmacology - Health - 21.03.2015
Novartis’ Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients
After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response New data at AAD shows 7 out of 10 psoriasis patients, who were PASI 75 responders at 52 Weeks, had almost clear to clear skin (PASI 90 to PASI 100) after two years of Cosentyx 300 mg treatment Cosentyx is the first and only IL-17A inhibitor approved in Europe, the US, Japan, Canada and Switzerland for moderate-to-severe pl

Pharmacology - Health - 20.03.2015
New Novartis data shows Cosentyx(TM) is significantly superior to Stelara and clears skin (PASI 90) in nearly 80% of psoriasis patients
CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx (TM) compared to Stelara at Week 16 Cosentyx showed greater improvements to Stelara across all study endpoints up to Week 16, including PASI 100 and onset of action PASI 90 and PASI 100 are both considered important measures of treatment success for psoriasis patients, demonstrating clear to almost clear skin , Cosentyx, the fir

Pharmacology - Health - 17.03.2015
Novartis receives EU approval for Jakavi in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer
Jakavi (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with an overprod

Health - Pharmacology - 16.03.2015
EPFL tuberculosis non-profit receives major grant
EPFL tuberculosis non-profit receives major grant
EPFL spin-off "Innovative Medicines for Tuberculosis" (iM4TB) has been awarded nearly USD 750,000 by the Bill & Melinda Gates Foundation to develop a breakthrough drug against tuberculosis.

Pharmacology - Health - 13.03.2015
Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin
Detailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara in clearing skin (PASI 90 and PASI 100) New data from the long-term Phase III program to be presented demonstrating Cosentyx efficacy and safety over two years in psoriasis patients Cosentyx is the first and only IL-17A inhibitor approved in Europe, the US, Japan Canada and Switzerland for moderate-to-severe plaque psoriasis[2-4] - Novartis announced t

Pharmacology - Health - 06.03.2015
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the refere

Pharmacology - Health - 28.01.2015
Novartis announces study in NEJM showing Jakavi was superior to standard therapy in rare blood cancer polycythemia vera
Jakavi (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera Polycythemia vera (PV) is a blood canc

Pharmacology - Business / Economics - 27.01.2015
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
Net sales grew in FY 2014, with strong core margin expansion Net sales increased 1% (+3% cc ) to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7 b

Pharmacology - Health - 23.01.2015
Novartis Bexsero vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible dosin

Pharmacology - Health - 23.01.2015
Novartis drug Jakavi recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack Clinical data show Jakavi (ruxolitinib) si

Pharmacology - Health - 21.01.2015
Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients
Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A , Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis Approval based on the efficacy and safety outcomes from 10 Phase II and III studies which included over 3,990 adult patients with moderate-to-severe

Pharmacology - Health - 19.01.2015
Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients
Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects ; all other biologics are recommended for second-line therapy[2-4] Cosentyx showed superiority to Stelara in the Phase IIIb CLEAR study In Phase III studies, 70% or more Cosentyx 300 mg patients achieved clear skin (PASI 100) or almost clear skin (PASI 90) during the fi

Pharmacology - Health - 12.01.2015
Novartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patients
Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with technolo

Pharmacology - Health - 08.01.2015
Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA
P ivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant improvements

Pharmacology - Health - 07.01.2015
Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee
Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested indicat

Pharmacology - Health - 07.01.2015
Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology
Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for using CRISPR to engineer chimeric antigen receptor T-cells and hematopoietic stem cells Basel, Switzerland, January 7, 2015 - Novartis announced today that it has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology and Caribou Biosciences for the development of drug discovery tools.

Pharmacology - Health - 26.12.2014
First in the world regulatory approval of Novartis’ Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis
Novartis Global select country select business Cosentyx (secukinumab) approval is based on Phase III program demonstrating high, sustained efficacy in the skin clearance of moderate-to-severe plaque psoriasis and improvement of signs and symptoms of psoriatic arthritis[1-5] Many patients do not respond to or tolerate current psoriasis or psoriatic arthritis treatments, indicating an unmet need for new therapies for these diseases[6-11] Psoriatic

Health - Pharmacology - 23.12.2014
Alcon treatment Travatan receives EU approval for pediatric glaucoma patients
Novartis Global select country select business New indication to decrease elevated intraocular pressure in patients, aged two months to less than 18 years, with ocular hypertension or pediatric glauc

Health - Pharmacology - 16.12.2014
Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis Global select country select business Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels Signifor LAR, a next-generati

Health - Pharmacology - 12.12.2014
Novartis announces results of trial evaluating the use of Afinitor in first-line treatment in HER2+ advanced breast cancer at SABCS
Novartis Global select country select business BOLERO-1 trial explored everolimus in women with HER2+ advanced breast cancer and did not meet criteria for statistical significance in first primary ob

Pharmacology - Health - 12.12.2014
Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara in clearing skin
Novartis Global select country select business Cosentyx showed superiority to Stelara ; meeting the primary endpoint of achieving PASI 90, which represents clear or almost clear skin at Week 16 and secondary endpoint of achieving PASI 75 at Week 4 for psoriasis patients CLEAR is the second head-to-head study for Cosentyx following the Phase III FIXTURE study that showed Cosentyx was superior to Enbrel (etanercept) CHMP recommended Cosentyx as fi

Pharmacology - Health - 08.12.2014
Novartis announces safety and efficacy benefit of Jakavi in global clinical trial of over 1,000 patients with myelofibrosis
Data from ongoing trial reinforces the safety profile of Jakavi (ruxolitinib) as seen in previous Phase III studies Patients on Jakavi experienced a reduction in spleen size that was maintained over

Pharmacology - Health - 08.12.2014
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN
Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online as part of the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Holzkirchen, December 8, 2014 - Sandoz, a Novartis company, announced today Phase III data that demonstrat

Health - Pharmacology - 06.12.2014
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions Additionally, sustained remissions were achieved up to one year or more with 6-month event-free survival of 70% and overall survival of 75%, in most cases without further therapy Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR'T cell therapies for the investi

Pharmacology - Health - 02.12.2014
Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia Studies targeting multiple cancer pathways in rare blood cancer m

Pharmacology - Health - 01.12.2014
Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)
PPMS is distinct from other types of MS, with no approved treatment that can change the course of this devastating disease Novartis remains strongly committed to identifying and developing treatment options for patients with chronic debilitating neurological conditions Basel, Dec 1, 2014 - Novartis announced today that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability measures.

Health - Pharmacology - 28.11.2014
Novartis’ heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]
LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening the formal review clock by 60 days Approximately 15 million people in the EU live with heart f

Pharmacology - Health - 25.11.2014
Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589
Basel , November 25, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has extended their priority review period by up to three months for the new drug application (NDA)

Pharmacology - Health - 24.11.2014
Novartis drug Signifor approved in EU, marking an advance for patients with inadequately controlled acromegaly
Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease , , , Approval based on two large phase III trials sho

Pharmacology - Health - 21.11.2014
Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients
Cosentyx (secukinumab, formerly AIN457) is recommended as first-line systemic therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients in Europe In Phase III studies, 70% or

Health - Pharmacology - 17.11.2014
Nine new analyses show Novartis’ LCZ696 could change course of heart failure for patients[1],[2]
New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril Patients' and doctors' assessments of disease severity were also significantly better with LCZ696 than enalapril Effects on certain heart biomarkers indicate that compared to enalapril, LCZ696 reduced cardiac stress and damage Heart failure is hig

Pharmacology - Health - 16.11.2014
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Secukinumab demonstrated significant and sustained efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA) in two pivotal studies - FUTURE 1 and FUTURE 2 are the first Phase III studies of a selective IL-17A inhibitor in PsA, a painful, debilitating condition causing inflammation of joints and skin , In FUTURE 1 more than 80% of secukinumab-treated patients experienced no progression of joint structural damage

This site uses cookies and analysis tools to improve the usability of the site. More information. |